ITOS — iTeos Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $297.39m
- -$222.98m
- $35.00m
- 71
- 31
- 55
- 51
Annual income statement for iTeos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 345 | 268 | 12.6 | 35 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 45.2 | 99.9 | 141 | 164 | 195 |
| Operating Profit | -45.2 | 245 | 126 | -151 | -160 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -38.1 | 256 | 149 | -109 | -120 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -38 | 215 | 96.7 | -113 | -134 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -38 | 215 | 96.7 | -113 | -134 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -43.4 | 215 | 96.7 | -113 | -134 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.24 | 5.68 | 2.56 | -3.15 | -3.32 |